NO20030022L - Syreaddisjonssalter av hydropyridinderivater - Google Patents

Syreaddisjonssalter av hydropyridinderivater

Info

Publication number
NO20030022L
NO20030022L NO20030022A NO20030022A NO20030022L NO 20030022 L NO20030022 L NO 20030022L NO 20030022 A NO20030022 A NO 20030022A NO 20030022 A NO20030022 A NO 20030022A NO 20030022 L NO20030022 L NO 20030022L
Authority
NO
Norway
Prior art keywords
therapeutic agent
acid addition
addition salts
preventive
addition salt
Prior art date
Application number
NO20030022A
Other languages
English (en)
Other versions
NO328651B1 (no
NO20030022D0 (no
Inventor
Fumitoshi Asai
Taketoshi Ogawa
Hideo Naganuma
Naotoshi Yamamura
Teruhiko Inoue
Kazuyoshi Nakamura
Original Assignee
Ube Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26595526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20030022(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ube Industries filed Critical Ube Industries
Publication of NO20030022D0 publication Critical patent/NO20030022D0/no
Publication of NO20030022L publication Critical patent/NO20030022L/no
Publication of NO328651B1 publication Critical patent/NO328651B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
NO20030022A 2000-07-06 2003-01-03 Syreaddisjonssalter av et hydropyridinderivat, medikamenter som inneholder disse, anvendelse av saltene til fremstilling av medikamenter og fremgangsmate for fremstilling av syreaddisjonssaltene av hydropyridinderivatet NO328651B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000205396 2000-07-06
JP2000266780 2000-09-04
PCT/JP2001/005764 WO2002004461A1 (fr) 2000-07-06 2001-07-03 Sels d'addition acides de dérivés hydropyridine

Publications (3)

Publication Number Publication Date
NO20030022D0 NO20030022D0 (no) 2003-01-03
NO20030022L true NO20030022L (no) 2003-03-05
NO328651B1 NO328651B1 (no) 2010-04-19

Family

ID=26595526

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030022A NO328651B1 (no) 2000-07-06 2003-01-03 Syreaddisjonssalter av et hydropyridinderivat, medikamenter som inneholder disse, anvendelse av saltene til fremstilling av medikamenter og fremgangsmate for fremstilling av syreaddisjonssaltene av hydropyridinderivatet

Country Status (24)

Country Link
US (1) US6693115B2 (no)
EP (2) EP1728794B1 (no)
KR (6) KR20090033917A (no)
CN (1) CN1214031C (no)
AT (2) ATE346071T1 (no)
AU (2) AU6791601A (no)
BR (1) BR0112168A (no)
CA (2) CA2415558C (no)
CY (3) CY1107554T1 (no)
CZ (1) CZ302990B6 (no)
DE (2) DE60134508D1 (no)
DK (2) DK1728794T3 (no)
ES (2) ES2308633T3 (no)
HK (2) HK1051362A1 (no)
HU (2) HU230762B1 (no)
IL (2) IL153546A0 (no)
MX (1) MXPA03000031A (no)
NO (1) NO328651B1 (no)
NZ (1) NZ523416A (no)
PL (1) PL208386B1 (no)
PT (2) PT1728794E (no)
RU (1) RU2238275C1 (no)
TW (1) TWI290927B (no)
WO (1) WO2002004461A1 (no)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1350511B1 (en) 2000-12-25 2008-09-10 Daiichi Sankyo Company, Limited Medicinal compositions containing aspirin
MXPA05000726A (es) * 2002-07-18 2005-04-08 Sankyo Co Composicion medicinal para tratar arteriosclerosis.
EP1660183A2 (en) * 2003-05-05 2006-05-31 Eli Lilly and Company Treating cardiovascular diseases with a compound of formula 1 (cs 747 - prasugrel; rn 150322-43-4)
US20060099261A1 (en) * 2004-11-08 2006-05-11 Biokey, Inc. Methods and formulations for making controlled release oral dosage form
US8586085B2 (en) * 2004-11-08 2013-11-19 Biokey, Inc. Methods and formulations for making pharmaceutical compositions containing bupropion
US20060099262A1 (en) * 2004-11-08 2006-05-11 Biokey, Inc. Methods and formulations for making controlled release oral dosage form
CN1318428C (zh) * 2005-02-23 2007-05-30 天津药物研究院 噻吩并吡啶取代的乙酰肼衍生物
TWI318571B (en) * 2005-06-10 2009-12-21 Lilly Co Eli Formulation of a thienopyridine platelet aggregation inhibitor
US20090156632A1 (en) * 2005-06-17 2009-06-18 John Thomas Brandt Dosage regimen for prasugrel
WO2007024472A2 (en) * 2005-08-19 2007-03-01 Eli Lilly And Company USE OF PAR- l/PAR- 4 INHIBITORS FOR TREATING OR PREVENTING VASCULAR DISEASES
US8056072B2 (en) 2005-10-31 2011-11-08 Microsoft Corporation Rebootless display driver upgrades
SI2007362T1 (sl) 2006-04-04 2018-12-31 Kg Acquisition Llc Peroralne odmerne oblike, ki vključujejo antitrombocitno sredstvo in inhibitor kisline
TWI392681B (zh) * 2006-04-06 2013-04-11 Daiichi Sankyo Co Ltd 高純度普拉格雷及其酸加成鹽之製法
SI2032521T1 (sl) * 2006-06-27 2010-02-26 Sandoz Ag Nov postopek za pripravo soli
WO2008060934A2 (en) * 2006-11-14 2008-05-22 Acusphere, Inc. Formulations of tetrahydropyridine antiplatelet agents for parenteral or oral administration
KR101442862B1 (ko) * 2006-12-07 2014-09-22 다이이찌 산쿄 가부시키가이샤 만니톨 또는 유당을 함유하는 고형 제제
TWI442947B (zh) * 2006-12-07 2014-07-01 Daiichi Sankyo Co Ltd 安定性經改善之薄膜塗覆製劑
EP2100608A4 (en) * 2006-12-07 2009-12-09 Daiichi Sankyo Co Ltd METHOD FOR PRODUCING A SOLID PREPARATION
CA2672154C (en) * 2006-12-07 2014-11-18 Daiichi Sankyo Company, Limited Pharmaceutical composition having improved storage stability
JP5274261B2 (ja) * 2006-12-07 2013-08-28 第一三共株式会社 低置換度ヒドロキシプロピルセルロースを含有する医薬組成物
MX2009009413A (es) * 2007-03-02 2009-09-11 Daiichi Sankyo Co Ltd Metodo para la produccion de clorhidrato de prasugrel de alta pureza.
WO2008134600A1 (en) 2007-04-27 2008-11-06 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
CZ302135B6 (cs) * 2007-07-09 2010-11-10 Zentiva, A. S. Zpusob výroby 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4, 5, 6, 7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu (prasugrelu)
WO2009062044A2 (en) * 2007-11-09 2009-05-14 Dr. Reddy's Laboratories Ltd. Processes for the preparation of prasugrel, and its salts and polymorphs
HU230261B1 (hu) * 2007-11-27 2015-11-30 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Eljárás gyógyszeripari intermedierek előállítására
CN101177430A (zh) * 2007-12-11 2008-05-14 鲁南制药集团股份有限公司 氢化吡啶衍生物及其盐的制备方法
US20110003847A1 (en) * 2008-02-06 2011-01-06 Helm Ag Prasugrel Salts with Improved Properties
WO2009129983A1 (en) * 2008-04-21 2009-10-29 Ratiopharm Gmbh Acid addition salts of prasugrel and pharmaceutical compositions comprising the same
PL2112155T3 (pl) 2008-04-25 2011-03-31 Sandoz Ag Wodorosiarczan (VI) 2-acetoksy-5-(α-cyklopropylokarbonylo-2-fluorobenzylo)-4,5,6,7-tetrahydrotieno[3,2-c]pirydyny i sposób jego otrzymywania
US20090281136A1 (en) * 2008-05-08 2009-11-12 Sandeep Mhetre Prasugrel pharmaceutical formulations
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US8759316B2 (en) * 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) * 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
KR20110045034A (ko) * 2008-08-02 2011-05-03 루난 파마슈티컬 그룹 코퍼레이션 프라수그렐 황산수소염 및 이의 약제학적 조성물 및 용도
EP2398468B1 (en) 2009-02-17 2016-11-30 KRKA, D.D., Novo Mesto Pharmaceutical compositions comprising prasugrel base or its pharmaceutically acceptable acid addition salts and processes for their preparation
RU2484094C1 (ru) * 2009-03-31 2013-06-10 Шанхай Инститьют Оф Фармасьютикал Индастри Кристаллы гидробромата прасугреля
EP3061460A1 (en) 2009-04-10 2016-08-31 Tufts Medical Center, Inc. Par-1 activation by metalloproteinase-1 (mmp-1)
KR20190071006A (ko) 2009-05-13 2019-06-21 사이덱스 파마슈티칼스, 인크. 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법
WO2011004392A1 (en) * 2009-07-06 2011-01-13 Glenmark Generics Limited Crystalline form of prasugrel hydrobromide, preparation and application thereof
DE102009036646A1 (de) 2009-08-07 2011-02-10 Ratiopharm Gmbh Prasugrel in nicht-kristalliner Form und pharmazeutische Zusammensetzung davon
CN101993447A (zh) 2009-08-26 2011-03-30 浙江华海药业股份有限公司 一种人工合成普拉格雷的方法
WO2011036533A1 (en) * 2009-09-23 2011-03-31 Glenmark Pharmaceuticals Limited Pharmaceutical composition comprising prasugrel and triflusal
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
PL2498731T3 (pl) 2009-11-11 2020-07-13 Chiesi Farmaceutici S.P.A. Sposoby leczenia lub zapobiegania zakrzepicy w stencie
CZ2009763A3 (cs) 2009-11-16 2011-05-25 Zentiva, K. S. Zpusob výroby vysoce cistého 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu známého pod nechráneným názvem prasugrel a jeho nových farmaceuticky prijatelných solí.
CZ2009762A3 (cs) 2009-11-16 2011-05-25 Zentiva, K. S. Nové soli 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu známého pod nechráneným názvem prasugrel a zpusob jejich výroby
CZ2009828A3 (cs) 2009-12-09 2011-06-22 Zentiva, K.S. Zpusob prípravy hydrochloridu 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu (prasugrelu hydrochloridu) v polymorfní forme B
HU229035B1 (en) * 2009-12-21 2013-07-29 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Process for producing prasurgel
WO2011092720A2 (en) * 2010-02-01 2011-08-04 Msn Laboratories Limited Pharmaceutical composition of prasugrel and its pharmaceutically acceptable salts
EP2360159A1 (de) * 2010-02-11 2011-08-24 Ratiopharm GmbH Prasugrel in mikronisierter, kristalliner Form und pharmazeutische Zusammensetzung davon
EP2545059A1 (en) 2010-03-09 2013-01-16 Synthon BV A process for making prasugrel
KR101184915B1 (ko) 2010-03-11 2012-09-21 한미사이언스 주식회사 고순도 프라수그렐의 제조방법
CA2788764A1 (en) 2010-03-23 2011-09-29 Alembic Pharmaceuticals Limited A process for the preparation of prasugrel hcl salt
EP2377520A1 (de) 2010-03-24 2011-10-19 Ratiopharm GmbH Pharmazeutische Zusammensetzung des Prasugrels
CN102212068A (zh) * 2010-04-06 2011-10-12 刘桂坤 噻吩衍生物及其制备方法和在药物上的应用
US8802854B2 (en) 2010-04-08 2014-08-12 Teva Pharmaceutical Industries Ltd. Crystalline forms of Prasugrel salts
CN102212071B (zh) * 2010-04-08 2014-03-26 上海医药工业研究院 普拉格雷盐酸盐乙酸溶剂合物及其结晶和制备方法
US20130203668A1 (en) 2010-04-19 2013-08-08 Cadila Healthcare Limited Pharmaceutical composition comprising antiplatelet agents and an erythropoiesis stimulating agent
WO2012001486A1 (en) * 2010-06-28 2012-01-05 Mayuka Labs Pvt. Ltd. An improved process for the preparation of prasugrel hydrochloride and its intermediates
TR201005900A1 (tr) 2010-07-19 2012-02-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Geliştirilmiş stabiliteye sahip prasugrel granülleri.
TR201006802A1 (tr) * 2010-08-17 2012-03-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Prasugrelin oral yolla dağılan formülasyonları.
EP2409685A3 (en) 2010-07-19 2012-02-01 Sanovel Ilac Sanayi ve Ticaret A.S. Orally-disintegrating formulations of prasugrel
TR201007926A1 (tr) 2010-07-19 2012-02-21 Sanovel İlaç San.Ve Ti̇c.A.Ş. Prasugrel tablet formülasyonları.
WO2012023145A2 (en) * 2010-08-18 2012-02-23 Hetero Research Foundation Prasugrel hydrochloride crystalline particles
HUP1000565A2 (en) 2010-10-22 2012-05-02 Egis Gyogyszergyar Nyrt Process for the preparation of pharmaceutically active compound and intermediers
CN101985450B (zh) * 2010-11-02 2012-07-11 北京赛科药业有限责任公司 普拉格雷盐及其制备方法
CN102532157A (zh) * 2010-12-16 2012-07-04 瑞阳制药有限公司 普拉格雷的可药用酸加成盐化合物及其制备方法
CZ305314B6 (cs) * 2010-12-30 2015-07-29 Zentiva, K.S. Nový hydrobromid formy C 5-[2-cyklopropyl-1-(2-fluorofenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu známého pod nechráněným názvem prasugrel a způsob jeho výroby
CN102199163A (zh) * 2011-04-01 2011-09-28 中国药科大学 2-羟基四氢噻吩并吡啶衍生物及其制备方法与在制药中的用途
CN102746318A (zh) * 2011-04-20 2012-10-24 上海信谊药厂有限公司 用于制备普拉格雷盐酸盐的方法
EP2709446A2 (en) 2011-05-17 2014-03-26 Velico Medical, Inc. Platelet storage using a sialidase inhibitor
US9788539B2 (en) 2011-05-17 2017-10-17 Velico Medical, Inc. Platelet protection solution having beta-galactosidase and sialidase inhibitors
CN102838618A (zh) * 2011-06-22 2012-12-26 广东东阳光药业有限公司 一种制备普拉格雷的方法及普拉格雷盐酸盐新晶型
EP2985023A1 (en) 2011-07-28 2016-02-17 Laboratorios Lesvi, S.L. Process for preparing prasugrel
CN103102355A (zh) * 2011-11-09 2013-05-15 丁克 具有旋光性的四氢噻吩并吡啶化合物
CZ2011872A3 (cs) 2011-12-22 2013-07-03 Zentiva, K.S. Farmaceutická formulace prasugrelu hydrobromidu
US8603537B2 (en) 2012-04-02 2013-12-10 Egis Pharmaceuticals Plc Prasugrel containing quickly released stable oral pharmaceutical compositions
EP2903430A1 (en) 2012-10-05 2015-08-12 Velico Medical, Inc. Platelet additive solution having a beta-galactosidase inhibitor
WO2014060560A1 (en) 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Solid oral formulations of prasugrel
WO2014060554A1 (en) 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Prasugrel formulations
PL402028A1 (pl) 2012-12-12 2014-06-23 Instytut Farmaceutyczny Sposób wytwarzania postaci polimorficznej B chlorowodorku prasugrelu o czystości farmaceutycznej
HU230649B1 (hu) 2013-01-24 2017-05-29 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Javított eljárás prasugrel gyógyszeripari hatóanyag és az 1-ciklopropil-2-(2-fluorofenil)-etanon intermedier előállítására
WO2014120886A1 (en) 2013-01-30 2014-08-07 Velico Medical, Inc. Platelet additive solution having a self-assembling hydrogel-forming peptide
KR102235732B1 (ko) 2013-12-26 2021-04-02 에스케이플래닛 주식회사 쿠폰 관리 시스템 및 방법, 그리고 이를 위한 장치 및 컴퓨터 프로그램이 기록된 기록매체
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
EP2979693A1 (en) 2014-08-01 2016-02-03 Zaklady Farmaceutyczne Polpharma SA Pharmaceutical composition comprising prasugrel or pharmaceutically acceptable salt thereof and process for its preparation
CN104479502A (zh) * 2014-12-31 2015-04-01 江阴市天邦涂料股份有限公司 一种水性防腐涂料
WO2016122421A1 (en) 2015-01-29 2016-08-04 Pharmactive Ilaç Sanayi Ve Ticaret A.Ş. Stable pharmaceutical compositions containing prasugrel base
EP3106151A1 (en) 2015-06-19 2016-12-21 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical compositions of prasugrel hydrobromide
EP3156049A1 (en) 2015-10-15 2017-04-19 Alembic Pharmaceuticals Limited Pharmaceutical composition of prasugrel
EP3158993A1 (en) 2015-10-22 2017-04-26 Zaklady Farmaceutyczne Polpharma SA Process for preparing a tablet comprising prasugrel or pharmaceutically acceptable salt thereof
HU231079B1 (hu) 2016-06-23 2020-06-29 Richter Gedeon Nyrt. Eljárás nagytisztaságú Prasugrel előállítására bromopentil szennyezés eltávolításával
EP3528790A1 (en) 2016-10-21 2019-08-28 Laboratorios Lesvi S.L. Pharmaceutical formulations of prasugrel and processes for the preparation thereof
CN106632391A (zh) * 2016-12-23 2017-05-10 山东鲁抗医药股份有限公司 一种盐酸普拉格雷化合物及其制备方法和含有盐酸普拉格雷的药物组合物
BR112019022676A2 (pt) 2017-06-23 2020-05-19 Chiesi Farm Spa método de prevenção de trombose de derivação da artéria sistêmica-para-pulmonar
KR102063862B1 (ko) 2018-08-09 2020-01-08 한국기술교육대학교 산학협력단 Qr코드 기반의 공유시점관리 시스템
KR102485021B1 (ko) 2020-11-18 2023-01-05 효성중공업 주식회사 델타구조 반도체변압기 기반 에너지 저장장치의 SoC 균등제어 장치 및 방법
KR102491932B1 (ko) 2020-11-18 2023-01-27 현대엠시스템즈 주식회사 통신 방식 가변형 원격 모니터링 제어 시스템 및 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141894A (en) * 1976-11-02 1979-02-27 Eli Lilly And Company Trans-5a-aryl-decahydrobenzazepines
FR2576901B1 (fr) 1985-01-31 1987-03-20 Sanofi Sa Nouveaux derives de l'acide a-(oxo-2 hexahydro-2,4,5,6,7,7a thieno (3,2-c) pyridyl-5) phenyl acetique, leur procede de preparation et leur application therapeutique
JP2506376B2 (ja) * 1987-07-16 1996-06-12 三菱化学株式会社 ２−（４−メチルアミノブトキシ）ジフェニルメタン・塩酸塩の製造方法
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
US5342851A (en) * 1992-10-07 1994-08-30 Mcneil-Ppc, Inc. Substituted thiazole derivatives useful as platelet aggregation inhibitors
JPH07188168A (ja) * 1993-12-28 1995-07-25 Fujisawa Pharmaceut Co Ltd ジヒドロピリジン化合物およびその製造方法
EP1350511B1 (en) * 2000-12-25 2008-09-10 Daiichi Sankyo Company, Limited Medicinal compositions containing aspirin
CZ2009762A3 (cs) 2009-11-16 2011-05-25 Zentiva, K. S. Nové soli 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu známého pod nechráneným názvem prasugrel a zpusob jejich výroby
CZ305314B6 (cs) 2010-12-30 2015-07-29 Zentiva, K.S. Nový hydrobromid formy C 5-[2-cyklopropyl-1-(2-fluorofenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu známého pod nechráněným názvem prasugrel a způsob jeho výroby

Also Published As

Publication number Publication date
KR20030014294A (ko) 2003-02-15
IL153546A0 (en) 2003-07-06
NO328651B1 (no) 2010-04-19
NZ523416A (en) 2004-10-29
DE60134508D1 (de) 2008-07-31
HU230762B1 (hu) 2018-03-28
EP1298132A4 (en) 2004-03-10
KR20090033917A (ko) 2009-04-06
PT1298132E (pt) 2007-01-31
CA2415558A1 (en) 2002-01-17
DE60124712T2 (de) 2007-09-13
KR20120062906A (ko) 2012-06-14
US6693115B2 (en) 2004-02-17
HU227746B1 (en) 2012-02-28
CY1110395T1 (el) 2015-04-29
HK1096684A1 (en) 2007-07-20
WO2002004461A1 (fr) 2002-01-17
KR20080021152A (ko) 2008-03-06
CN1214031C (zh) 2005-08-10
CY1107554T1 (el) 2010-07-28
KR20100105763A (ko) 2010-09-29
IL153546A (en) 2007-03-08
CY2009011I2 (el) 2010-07-28
EP1728794A1 (en) 2006-12-06
CY2009011I1 (el) 2010-07-28
DK1728794T3 (da) 2008-09-22
EP1298132B1 (en) 2006-11-22
CZ302990B6 (cs) 2012-02-08
HUP1100350A2 (en) 2003-09-29
ATE398624T1 (de) 2008-07-15
HUP0301645A3 (en) 2006-05-29
ES2276801T3 (es) 2007-07-01
MXPA03000031A (es) 2003-10-15
NO20030022D0 (no) 2003-01-03
AU6791601A (en) 2002-01-21
PT1728794E (pt) 2008-07-15
PL208386B1 (pl) 2011-04-29
EP1728794B1 (en) 2008-06-18
HUP0301645A2 (hu) 2003-09-29
CZ200318A3 (cs) 2003-05-14
ATE346071T1 (de) 2006-12-15
US20030134872A1 (en) 2003-07-17
KR20130118395A (ko) 2013-10-29
DE60124712D1 (de) 2007-01-04
CA2703697A1 (en) 2002-01-17
TWI290927B (en) 2007-12-11
AU2001267916B2 (en) 2004-09-09
CA2415558C (en) 2010-09-14
CA2703697C (en) 2012-09-04
CN1452624A (zh) 2003-10-29
RU2238275C1 (ru) 2004-10-20
PL359393A1 (en) 2004-08-23
BR0112168A (pt) 2003-09-02
HK1051362A1 (en) 2003-08-01
ES2308633T3 (es) 2008-12-01
DK1298132T3 (da) 2007-03-12
EP1298132A1 (en) 2003-04-02

Similar Documents

Publication Publication Date Title
NO20030022L (no) Syreaddisjonssalter av hydropyridinderivater
RU2003100082A (ru) Кислотные аддитивные соли производных гидропиридина
IL156456A0 (en) Pharmaceutical compositions containing aspirin
MXPA03000252A (es) Derivados de quinolina que tienen actividad de inhibicion de fcev.
IE883360L (en) Indan derivatives and process for preparation thereof
JP2003246735A5 (no)
AU631023B2 (en) Tetrahydronaphthalene derivatives and preparation thereof
EP1236735A4 (en) BENZAMIDINE DERIVATIVES
Plotkine et al. Oral administration of isosorbide dinitrate inhibits arterial thrombosis in rats
GR3008250T3 (no)

Legal Events

Date Code Title Description
MK1K Patent expired